Year All2026202520242023202220212020201920182017201620152014201320122011201020092008 Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results March 18, 2026 Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 March 11, 2026 Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) March 9, 2026 Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU January 30, 2026 Protalix BioTherapeutics Letter to Stockholders January 5, 2026
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 March 11, 2026
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) March 9, 2026
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU January 30, 2026